July 23, 2025 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the successful completion of site initiation at Tel Aviv Sourasky Medical Center (TASMC) for its Phase I/IIa clinical trial evaluating CMND-100, a proprietary oral drug candidate for Alcohol Use Disorder (AUD). This milesto

Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of WIN378 in patients with asthma, with a first data readout expected in mid-2026 WIN378 has the potential to be the first-to-market long-acting, anti-TSLP antibody with twice-yearly dosing in asthma and COPD Improved dosing convenience can meaningfully reduce treatment burden and improve outcomes for people living with advanced respiratory diseases COPD clinical program planned to start in mid-2026 July 23, 2025 -- Windward

July 22, 2025 -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for early allergen conta

July 22, 2025 -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it has entered into a collaboration with the U.S. Food and Drug Administration (FDA) to develop reference materials to improve regulatory standards and enhance analytical methods for ADC drug development. The collaboration will leverage Sutro’s cell-free XpressCF® technology to precisely engineer ADCs wi

Financing led by Suvretta Capital Management and SR One with participation from 16 additional healthcare investors Proceeds will support key clinical milestones across all of Avalyn’s pipeline programs July 22, 2025 -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced the closing of an oversubscribed $100 million Series D financing. The raise was co-led by Suv

July 21, 2025 -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escala

Findings published in the journal of Clinical Genitourinary Cancer show patients remained event-free for a median of two years after achieving complete response with ZUSDURI (mitomycin) intravesical solution. Among the 17 patients who achieved complete response and entered a long-term extension study, the median duration of response was 3.5 years by Kaplan-Meier estimate. July 21, 2025 -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovativ

ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia Following the FDA ODD, European designation underscores ICT01’s potential as a novel immunotherapy approach in AML July 21, 2025 – ImCheck Therapeutics today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A) monoclonal antibody designed to selectively activate γ9δ2 T cells, for the treat

Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population July 21, 2025 -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that topline firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study in first-line EGFR exon20 insertion mutant n

FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease July 21, 2025 - ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD), today announced that the U.S. Food and Drug Ad